Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "Androgen Receptor Pathway Inhibitors or Taxanes for Patients With mCRPC - A Direct Comparison in ProBio, a Randomized, Outcome-Adaptive, Biomarker-Driven Platform Trial"

86 views
October 30, 2023
Comments 0
Login to view comments. Click here to Login